Cyclophosphamide induces mRNA, protein and enzyme activity of cytochrome P450 in rat

References

• Angley MT, Sansom LN, Stupans I. 1995. Cyclophosphamide administered repeatedly to the male rat and as a single dose to the female rat. Its effects on hepatic and pulmonary P450 and associated enzymes. Xenobiotica 25:1051–1062.
   PubMed Web of Science ®Google Scholar
• Boddy AV, Yule SM. 2000. Metabolism and pharmacokinetics of oxazaphosphorines. Clinical Pharmacokinetics 38:291–304.
   PubMed Web of Science ®Google Scholar
• Chang TK, Waxman DJ. 1993. Cyclophosphamide modulates rat hepatic cytochrome P450 2C11 and steroid 5 alpha-reductase activity and messenger RNA levels through the combined action of acrolein and phosphoramide mustard. Cancer Research 53:2490–2497.
   PubMed Web of Science ®Google Scholar
• Chang TK, Yu L, Maurel P, Waxman DJ. 1997. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Research 57:1946–1954.
   PubMed Web of Science ®Google Scholar
• Clarke L, Waxman DJ. 1989. Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation. Cancer Research 49:2344–2350.
   PubMed Web of Science ®Google Scholar
• Edwards RJ, Price RJ, Watts PS, Renwick AB, Tredger JM, Boobis AR, Lake BG. 2003. Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metabolism and Disposition 31:282–288.
   PubMed Web of Science ®Google Scholar
• Fleming RA. 1997. An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy 17:146S–154S.
   Google Scholar
• Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V, Martin H, Beaune P, de Waziers I. 1999. Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 9:295–306.
   Google Scholar
• Gonzalez FJ. 1991. Human cytochrome P450: possible roles of drug-metabolizing enzymes and polymorphic drug oxidation in addiction. NIDA Research Monograph 111:202–213.
   PubMedGoogle Scholar
• Griskevicius L, Meurling L, Hassan M. 2002. Simple method based on fluorescent detection for the determination of 4-hydroxycyclophosphamide in plasma. Therapy and Drug Monitoring 24:405–409.
   PubMed Web of Science ®Google Scholar
• Hassan M, Svensson US, Ljungman P, Bjorkstrand B, Olsson H, Bielenstein M, Abdel-Rehim M, Nilsson C, Johansson M, Karlsson MO. 1999. A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients. British Journal of Clinical Pharmacology 48:669–677.
   PubMed Web of Science ®Google Scholar
• Huang Z, Roy P, Waxman DJ. 2000. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochemical Pharmacology 59:961–972.
   PubMed Web of Science ®Google Scholar
• Iwanari M, Nakajima M, Kizu R, Hayakawa K, Yokoi T. 2002. Induction of CYP1A1, CYP1A2, CYP1B1 mRNAs by nitropolycyclic aromatic hydrocarbons in various human tissue-derived cells: chemical-, cytochrome P450 isoform-, cell-specific differences. Archives in Toxicology 76:287–298.
   PubMed Web of Science ®Google Scholar
• Kikuchi H. 2002. [Regulation of cytochrome P-450 (CYP) genes by nuclear receptors]. Nippon Eiseigaku Zasshi 56:622–628.
   PubMedGoogle Scholar
• Kraner JC, Morgan ET, Poet TS, Born SL, Burnett VL, Halpert JR. 1996. Suppression of rat hepatic microsomal cytochromes P450 by cyclophosphamide is correlated with plasma thyroid hormone levels and displays differential strain sensitivity. Journal of Pharmacology and Experimental Therapy 276:258–264.
   PubMed Web of Science ®Google Scholar
• Laslett TJ, Alvarez F, Nation RL, Evans AM, Scott SD, Stupans I. 1995. Effect of cyclophosphamide administration on the activity and relative content of hepatic P4502D1 in rat. Xenobiotica 25:1031–1039.
   PubMed Web of Science ®Google Scholar
• LeBlanc GA, Waxman DJ. 1990. Mechanisms of cyclophosphamide action on hepatic P-450 expression. Cancer Research 50:5720–5726.
   PubMed Web of Science ®Google Scholar
• Lindley C, Hamilton G, McCune JS, Faucette S, Shord SS, Hawke RL, Wang H, Gilbert D, Jolley S, Yan B, LeCluyse EL. 2002. The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metabolism and Disposition 30:814–822.
   PubMed Web of Science ®Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurements with the folin phenol reagent. Journal of Biological Chemistry 193:265–275.
   PubMed Web of Science ®Google Scholar
• Lubet RA, Cameron JW, Nims RW, Burke MD, Wolff T, Guengerich FP. 1985. Dealkylation of pentoxyresorufin: a rapid and sensitive assay for measuring induction of cytochrome(s) P-450 by phenobarbital and other xenobiotics in the rat. Archives of Biochemistry and Biophysics 238:43–48.
   PubMed Web of Science ®Google Scholar
• McClure MT, Stupans I. 1992. Investigation of the mechanism by which cyclophosphamide alters cytochrome P450 in male rats. Biochemical Pharmacology 43:2655–2658.
   PubMed Web of Science ®Google Scholar
• McClure MT, Stupans I. 1995. Hormonal perturbation as a possible mechanism for the alteration of cytochrome P450 by cyclophosphamide. Biochemical Pharmacology 49:1827–1836.
   PubMed Web of Science ®Google Scholar
• McGuire TR, Gwilt P, Manouvilov K, Healey K, Ursick MM, Nash RA, Pavletic SZ. 2003. High-dose cyclophosphamide in multiple sclerosis patients undergoing autologous stem cell transplantation. International Immunopharmacology 3:279–283.
   PubMed Web of Science ®Google Scholar
• Mirghani RA, Ericsson O, Tybring G, Gustafsson LL, Bertilsson L. 2003. Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man. European Journal of Clinical Pharmacology 59:23–28.
   PubMed Web of Science ®Google Scholar
• Moore MJ, Hardy RW, Thiessen H, Soldin SJ, Erlichman C 1988. Rapid development of enhanced clearance after high-dose cyclophosphamide. Clinical Pharmacology and Therapy 44:622–628.
   PubMed Web of Science ®Google Scholar
• Nelson DR. 1999. Cytochrome P450 and the individuality of species. Archives of Biochemistry and Biophysics 369:1–10.
   PubMed Web of Science ®Google Scholar
• Pascussi JM, Gerbal-Chaloin S, Drocourt L, Maurel P, Vilarem MJ. 2003. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochimica et Biophysica Acta 16 19:243–253.
   Google Scholar
• Ren S, Kalhorn TF, McDonald GB, Anasetti C, Appelbaum FR, Slattery JT. 1998. Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients. Clinical Pharmacology and Therapy 64:289–301.
   PubMed Web of Science ®Google Scholar
• Roy P, Yu LJ, Crespi CL, Waxman DJ. 1999. Development of a substrate—activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metabolism and Disposition 27:655–666.
   PubMed Web of Science ®Google Scholar
• Schuler U, Ehninger G, Wagner T. 1987. Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites. Cancer Chemotherapy and Pharmacology 20:248–252.
   PubMed Web of Science ®Google Scholar
• Sohlenius-Sternbeck AK, Floby E, Svedling M, Orzechowski A. 2000. High conservation of both phase I and II drug-metabolizing activities in cryopreserved rat liver slices. Xenobiotica 30:891–903.
   PubMed Web of Science ®Google Scholar
• Von Bahr C, Groth CG, jansson H, Lundgren G, Lind M, Glaumann H. 1980. Drug metabolism in human liver in vitro: establishment of a human liver bank. Clinical Pharmacology and Therapy 27:711–725.
   PubMed Web of Science ®Google Scholar
• Xie HJ, Yasar U, Lundgren S, Griskevicius L, Terelius Y, Hassan M, Rane A. 2003a. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics Journal 3:53–61.
   PubMed Web of Science ®Google Scholar
• Xie HJ, Broberg U, Griskevicius L, Lundgren S, Carlens S, Meurling L, Paul C, Rane A, Hassan, M. 2003b. Alteration of pharmacokinetics of cyclophosphamide and suppression of the cytochrome P450 genes by ciprofloxacin. Bone Marrow Transplant 31:197–203.
   PubMed Web of Science ®Google Scholar
• Yu LJ, Drewes P, Gustafsson K, Brain EG, Hecht JE, Waxman DJ. 1999. In vivo modulation of alternative pathways of P-450-catalysed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity. Journal of Pharmacology and Experimental Therapy 288:928–937.
   PubMed Web of Science ®Google Scholar
• Zhao XJ, Ishizaki T. 1997. The In vitro hepatic metabolism of quinine in mice, rats and dogs: comparison with human liver microsomes. Journal of Pharmacology and Experimental Therapy 283:1168–1176.
   PubMed Web of Science ®Google Scholar